Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03125226 · ClinicalTrials.gov registry record · NA
TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT03125226 is a NA study that has completed, run by University of Washington. The registered enrollment target is 12 participants.
The verdict
NCT03125226, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may help doctors learn more about tumor location and altering radiation dosage for bladder cancer.
Interventions
- DEVICE Polyethylene Glycol Hydrogel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2020-05-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03125226
The ClinicalTrials.gov registry entry for NCT03125226 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Polyethylene Glycol Hydrogel is the first listed.
NCT03125226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03125226 about?
NCT03125226 is a clinical study titled "TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer". This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may ...
What is the current status of trial NCT03125226?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2017-10-05. Estimated completion is 2020-05-18.
What interventions are being tested in trial NCT03125226?
The interventions under investigation include: Polyethylene Glycol Hydrogel (DEVICE).
Who is sponsoring clinical trial NCT03125226?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.